En Español
A judge in the state of Pennsylvania, Judge Arnold New, has allowed users of the popular anti-blood clotting drug, Xarelto, the ability to file “Efficacy Claims” in the state’s multidistrict litigation.
This move now makes it possible for any additional claims to be filed against the makers of the drug, Xarelto.
Plaintiffs in the case have a deadline to file in the case after federal litigation Judge, Eldon Fallon, issued a Pretrial Order (No. 11E) for filing bundled MDL Xarelto claims at May 20, 2016, for short form complaints.
Any claims filed after the May 20th deadline will require the full filing fee. Further, law firms representing plaintiffs will no longer be able to file multiple claims under one filing fee. All claims that are filed after the May 20 deadline additionally are required to be filed according to Local Court Rules and FRCP.
When the blood thinner, Xarelto was first offered on the market, it seemed to be a more convenient way for patients to maintain the medical condition it sought to treat, consumers were unaware that it would have dangerous side effects.
Xarelto came on the market as a new classification of blood thinner in 201l for people who were at risk for forming blood clots. Being able to reverse the blood thinning process is important, however, users of the drug Xarelto found that the drug did not have a way to reverse the blood thinning process and dangerous situations arose in patients who used the drug.
If you or a loved one has been harmed by taking Xarelto, contact a Xarelto Lawsuit Attorney at John Foy & Associates to set up a free consultation.
